Fibroma of bone is a rare, locally aggressive bone tumor. Once it was called the osseous counterpart of extra-abdominal desmoid tumor, because of the histological aspects. In 2013, the WHO described the microscopic appearance of desmoplastic fibroma as being composed of slender, spindle to stellate cells with minimal cytological atypia and abundant collagenous matrix.
Contact:
Frank Traub MD, PhD | This email address is being protected from spambots. You need JavaScript enabled to view it.
Dimosthenis Andreou, M.D. | This email address is being protected from spambots. You need JavaScript enabled to view it.
Downloads
Desmoplastic Fibroma of bone.pdf135.88 KB
Desmoplastic Fibroma EMSOS study datasheet.xls48.00 KB
Desmoid-type fibromatosis is an intermediate soft tissue tumour (WHO) with clonal fibroblastic proliferation originating in the deep soft tissues. It is characterised by local infiltration without metastatic potential. In the past decades resectable masses have been mainly treated surgically with a high incidence of local recurrence in up to one third of the patients independently from resection margins. Local recurrence negative prognostic factors after surgery have been identified in younger age, female gender, distal limb location and recurrent disease.
Alternative management including radioterapy or medical treatment with NSAIDS, hormone therapy, chemotherapy and tyrosine kinase inhibitors led to high recurrence rate as well.
As a consequence in recent years the wait and see approach, with strict and close clinical and instrumental monitoring of the involved site has gained popularity as first line management for silent masses not involving neurovascular bundles.
Contact: Prof Domenico Andrea Campanacci | This email address is being protected from spambots. You need JavaScript enabled to view it.
DownloadsEMSOS Fibromatosis study.pdf131.83 KBEMSOS database.xls36.00 KB
Clear cell chondrosarcoma is a rare variant of chondrosarcoma, behaving as a low grade malignant bone tumor and characterized by a proliferation of tumor cells with clear cytoplasm.
Clear cell chondrosarcomas account for around 2% of all chondrosarcomas. They have been described in most bones of the body but usually affect the proximal epiphysis of the humerus or femur.
Doz. Dimosthenis Andreou, Münster, Germany
This email address is being protected from spambots. You need JavaScript enabled to view it.
DownloadsClear cell chondrosarcoma EMSOS study 20170906.pdf90.27 KBClear cell chondrosarcoma EMSOS study protocol.xls36.00 KB
Diffuse and nodular type Tenosynovial Giant Cell Tumour (TGCT), previously named Pigmented Villonodular Synovitis (PVNS), is a rare, locally aggressive, non-metastasizing neoplasm. Current literature primarily consists of several small cohorts containing relatively inhomogeneous data. Systematic-/meta-analysis at present are only describing or pooling their results. In order to predict outcome; individual data in one large cohort, containing important characteristics; e.g. frequency of local recurrence, extent or disease severity (nodular versus diffuse), influence of surgical technique (arthroscopic versus open synovectomy), primary treatment after referral, etc. is therefore essential.
Your help in gathering (un)published data and compile a global TGCT retrospective database, to help us evaluate this orphan disease, is much appreciated.
Monique Mastboom: This email address is being protected from spambots. You need JavaScript enabled to view it.
DownloadsTGCT global database EMSOSdef.xls524 KBTGCT global database EMSOS case inclusion protocol def.pdf496.3 KBHow to complete TGCT database def.pdf426.66 KB
